Table 1 Results of kinase inhibitor screen using the LATS-BS

From: A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis

Kinase inhibitor Target kinase Increased fold change
SU 4312 VEGFR1/2 27.88
PD 98059 MEK 16.9
BIO GSKa/b 14.38
API-2 PKB 10.57
Genistein EGFR 6.12
Ryuvidine CDK4 5.88
  1. The top kinase inhibitors that activated or inhibited the LATS-BS are shown. The primary target kinases (at 10 μM dose) and fold change in biosensor activity are described for each inhibitor
Kinase inhibitor Target kinase Suppressed fold change
Ro 08-2750 TrkA 6.51
Ro 31-8220 General 5.21
ER 27319 SYK 3.71
CGK 733 ATM/ATR 1.85
PD 407824 CHK1 1.73
GSK650394 SGK 1.73
  1. The top kinase inhibitors that activated or inhibited the LATS-BS are shown. The primary target kinases (at 10 μM dose) and fold change in biosensor activity are described for each inhibitor